Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

1,800

Employees1,800

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

1,800

Employees1,800

NBIX Key Statistics

Market cap

13.56B

Market cap13.56B

Price-Earnings ratio

40.33

Price-Earnings ratio40.33

Dividend yield

—

Dividend yield—

Average volume

917.26K

Average volume917.26K

High today

$139.29

High today$139.29

Low today

$135.81

Low today$135.81

Open price

$139.29

Open price$139.29

Volume

488.82K

Volume488.82K

52 Week high

$154.61

52 Week high$154.61

52 Week low

$84.23

52 Week low$84.23

NBIX News

TipRanks 3d

Neurocrine price target raised to $195 from $188 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Neurocrine (NBIX) to $195 from $188 and keeps a Buy rating on the shares. Investor attention on Neur...

TipRanks 6d

Neurocrine presents new data from KINECT-HD2 study of ingrezza

Neurocrine (NBIX) Biosciences presented new data from the open-label KINECT-HD2 study demonstrating an established long-term safety profile, tolerability and su...

Analyst ratings

86%

of 28 ratings

Buy

85.7%

Hold

14.3%

Sell

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.